Piromelatine

N/A

Report date: 2023/06/29 10:13:10
NME

Base Information

Drug NamePiromelatine
Drug Alias Namepiromelatinum吡美拉汀piromelatina匹罗美拉汀Neu-P11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMelatonin receptor 1A agonistsSerotonin 1a (5-HT1a) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists +[4] 
TargetsMelatonin receptor 1AMelatonin receptor 1BSerotonin 1a (5-HT1a) receptor +[4] 
Therapy Area/IndicationsGlaucoma, Open-AngleSleep Initiation and Maintenance DisordersAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeurim Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeurim Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsGlaucoma, Open-AngleAlzheimer Disease
Inactive IndicationsSleep Initiation and Maintenance Disorders

Other Information

ATC CodeN/A
Related LinksWikipedia